<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01383447</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2010-02202</org_study_id>
    <secondary_id>J1023</secondary_id>
    <secondary_id>U01CA070095</secondary_id>
    <nct_id>NCT01383447</nct_id>
  </id_info>
  <brief_title>Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Phase 1/2 Study of SNDX-275 in Combination With Imatinib for Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I/II trial is studying the side effects and best dose of entinostat when given
      together with imatinib mesylate and to see how well it works in treating patients with
      relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
      Entinostat and imatinib mesylate may stop the growth of cancer cells by blocking some of the
      enzymes needed for cell growth
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the maximum tolerated dose (MTD) of entinostat when given in combination with
      imatinib (matinib mesylate).

      SECONDARY OBJECTIVES:

      I. To estimate the rate of complete response (CR) for patients greater ≥ 18 years of age with
      relapsed/refractory Ph+ ALL treated with a combination of entinostat and imatinib.

      II. To estimate the 1 year progression free survival (PFS) for patients greater ≥ 18 years of
      age with relapsed/refractory Ph+ ALL treated with a combination of entinostat and imatinib
      III. To describe the comparative pharmacokinetics (PK) and pharmacodynamics (PD) of
      entinostat when administered alone vs. in combination with imatinib.

      IV. To assess the predictive value of levels of flow cytometric minimal residual disease
      (MRD) on duration of progression free survival for the study population.

      OUTLINE: This is a phase I, dose-escalation study of entinostat followed by a phase II study.

      Patients receive entinostat orally (PO) daily on days 1, 8, 15, and 22 and imatinib mesylate
      PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the
      absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was halted prematurely by the NCI for low accrual.
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Entinostat When Given in Combination With Imatinib Mesylate</measure>
    <time_frame>Up to 30 days post-treatment</time_frame>
    <description>The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Response (CR) for Adults With Relapsed/Refractory Ph+ ALL Treated With a Combination of Entinostat (at the Dose Determined in Phase 1) and Imatinib Mesylate</measure>
    <time_frame>Up to 30 days post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) for Adults With Relapsed/Refractory Ph+ ALL Treated With Combination of Entinostat and Imatinib Mesylate</measure>
    <time_frame>At 1 year</time_frame>
    <description>The Kaplan-Meier estimator will be used to estimate PFS with a 95% confidence interval from study entry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative Pharmacokinetics (PK) and Pharmacodynamics (PD) of Entinostat Alone vs. Entinostat Plus Imatinib Mesylate</measure>
    <time_frame>Day 4 and 11</time_frame>
    <description>Entinostat concentrations will be compared when administered alone or in combination with imatinib by paired Student's t test (day 4 vs 11 concentrations) or Wilcoxon signed rank tests as appropriate. Association between exposure parameters and PD endpoints (e.g., apoptosis, histone acetylation, BCR-ABL expression) will be assessed using Fisher's exact tests or Wilcoxon rank sum tests as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive Values of Levels of Flow Cytometric Minimal Residual Disease (MRD) on Duration of Progression Free Survival for the Study Population</measure>
    <time_frame>Day 29</time_frame>
    <description>Kaplan-Meier PFS curves and cumulative incidence of progression curves will be generated for patients above vs. below each threshold, and log rank will be used to compare the curves.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>entinostat</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
    <other_name>HDAC inhibitor SNDX-275</other_name>
    <other_name>SNDX-275</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
    <other_name>CGP 57148</other_name>
    <other_name>Gleevec</other_name>
    <other_name>Glivec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>western blotting</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
    <other_name>Blotting, Western</other_name>
    <other_name>Western Blot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
    <other_name>immunohistochemistry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
    <other_name>PCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>high performance liquid chromatography</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
    <other_name>HPLC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mass spectrometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically confirmed BCR-ABL1 associated (Ph+) acute
             lymphoblastic leukemia (ALL) with primary refractory or relapsed disease;
             demonstration of BCR-ABL1 in leukemia cells by one or more of the following is
             required: t(9;22)(q34;q11.2) cytogenetics; FISH for BCR-ABL1 fusion; RT-PCR for
             BCR-ABL1 fusion

          -  Prior treatment with tyrosine kinase inhibitors (including imatinib, nilotinib and/or
             dasatinib) is allowed, although patients must be off any tyrosine kinase inhibitor for
             a minimum of 72 hours prior to beginning protocol therapy

          -  ECOG performance status of 0, 1 or 2

          -  Total WBC =&lt; 150,000 with no evidence for ongoing or impending leukostasis

          -  Total bilirubin =&lt; 2.0 mg/dL unless elevated due to Gilbert's, hemolysis or leukemic
             infiltration

          -  Aspartate transaminase (AST)/alanine transaminase (ALT) =&lt; 2.5 × upper limit of normal
             (ULN) unless due to leukemic infiltration

          -  Serum creatinine =&lt; 2.0 mg/dL or creatinine clearance &gt; 50 ml/min

          -  Left ventricular ejection fraction (LVEF) &gt;= 45% as measured by echocardiogram (ECHO)
             or MUGA

          -  Patients who have undergone stem cell transplantation (SCT), autologous or allogeneic,
             are eligible provided that they are &gt; 4 weeks from stem cell infusion, have no active
             GVHD, and meet other eligibility criteria

          -  Patients who fail primary induction therapy or relapse after achieving complete
             remission (CR) are eligible if they are &gt; 3 weeks off cytotoxic chemotherapy and &gt; 2
             weeks off radiation therapy; patients must be off biologic therapies including
             hematopoietic growth factors &gt; 1 week; if using hydroxyurea (HU), steroids, or other
             non-cytotoxics for blast count control, patient must be off for &gt; 24 hrs before
             starting protocol therapy; patients must have recovered from all acute toxicities from
             any previous therapy

          -  Female patients of childbearing age must have negative pregnancy test; women of
             child-bearing potential and men must agree to use adequate contraception (hormonal or
             barrier method of birth control; abstinence) prior to study entry and for the duration
             of study participation; should a woman become pregnant or suspect she is pregnant
             while participating in this study, she should inform her treating physician
             immediately

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients may not be receiving any other investigational agents

          -  Active CNS leukemia; patients with known previous CNS leukemia may continue to receive
             intrathecal therapy with ara-C, methotrexate, and/or thiotepa plus steroids as
             prophylaxis against reactivation of previous CNS disease

          -  Patients may not have received previous treatment with entinostat or other HDAC
             inhibitors

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to entinostat or other agents used in study

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             untreated infection, symptomatic congestive heart failure, unstable angina pectoris,
             unstable cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with study requirements

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated with entinostat

          -  HIV-positive patients on combination antiretroviral therapy are ineligible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Brown</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-8936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>June 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2011</study_first_posted>
  <results_first_submitted>April 14, 2017</results_first_submitted>
  <results_first_submitted_qc>July 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 8, 2017</results_first_posted>
  <last_update_submitted>July 7, 2017</last_update_submitted>
  <last_update_submitted_qc>July 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entinostat</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Entinostat and Imatinib Mesylate)</title>
          <description>Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
entinostat: Given PO
imatinib mesylate: Given PO
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies
western blotting: Correlative studies
immunohistochemistry staining method: Correlative studies
flow cytometry: Correlative studies
polymerase chain reaction: Correlative studies
high performance liquid chromatography: Correlative studies
mass spectrometry: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Entinostat and Imatinib Mesylate)</title>
          <description>Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
entinostat: Given PO
imatinib mesylate: Given PO
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies
western blotting: Correlative studies
immunohistochemistry staining method: Correlative studies
flow cytometry: Correlative studies
polymerase chain reaction: Correlative studies
high performance liquid chromatography: Correlative studies
mass spectrometry: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of Entinostat When Given in Combination With Imatinib Mesylate</title>
        <description>The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting.</description>
        <time_frame>Up to 30 days post-treatment</time_frame>
        <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Entinostat and Imatinib Mesylate)</title>
            <description>Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
entinostat: Given PO
imatinib mesylate: Given PO
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies
western blotting: Correlative studies
immunohistochemistry staining method: Correlative studies
flow cytometry: Correlative studies
polymerase chain reaction: Correlative studies
high performance liquid chromatography: Correlative studies
mass spectrometry: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of Entinostat When Given in Combination With Imatinib Mesylate</title>
          <description>The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting.</description>
          <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Complete Response (CR) for Adults With Relapsed/Refractory Ph+ ALL Treated With a Combination of Entinostat (at the Dose Determined in Phase 1) and Imatinib Mesylate</title>
        <time_frame>Up to 30 days post-treatment</time_frame>
        <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Entinostat and Imatinib Mesylate)</title>
            <description>Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
entinostat: Given PO
imatinib mesylate: Given PO
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies
western blotting: Correlative studies
immunohistochemistry staining method: Correlative studies
flow cytometry: Correlative studies
polymerase chain reaction: Correlative studies
high performance liquid chromatography: Correlative studies
mass spectrometry: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Complete Response (CR) for Adults With Relapsed/Refractory Ph+ ALL Treated With a Combination of Entinostat (at the Dose Determined in Phase 1) and Imatinib Mesylate</title>
          <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS) for Adults With Relapsed/Refractory Ph+ ALL Treated With Combination of Entinostat and Imatinib Mesylate</title>
        <description>The Kaplan-Meier estimator will be used to estimate PFS with a 95% confidence interval from study entry.</description>
        <time_frame>At 1 year</time_frame>
        <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Entinostat and Imatinib Mesylate)</title>
            <description>Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
entinostat: Given PO
imatinib mesylate: Given PO
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies
western blotting: Correlative studies
immunohistochemistry staining method: Correlative studies
flow cytometry: Correlative studies
polymerase chain reaction: Correlative studies
high performance liquid chromatography: Correlative studies
mass spectrometry: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) for Adults With Relapsed/Refractory Ph+ ALL Treated With Combination of Entinostat and Imatinib Mesylate</title>
          <description>The Kaplan-Meier estimator will be used to estimate PFS with a 95% confidence interval from study entry.</description>
          <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparative Pharmacokinetics (PK) and Pharmacodynamics (PD) of Entinostat Alone vs. Entinostat Plus Imatinib Mesylate</title>
        <description>Entinostat concentrations will be compared when administered alone or in combination with imatinib by paired Student’s t test (day 4 vs 11 concentrations) or Wilcoxon signed rank tests as appropriate. Association between exposure parameters and PD endpoints (e.g., apoptosis, histone acetylation, BCR-ABL expression) will be assessed using Fisher’s exact tests or Wilcoxon rank sum tests as appropriate.</description>
        <time_frame>Day 4 and 11</time_frame>
        <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Entinostat and Imatinib Mesylate)</title>
            <description>Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
entinostat: Given PO
imatinib mesylate: Given PO
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies
western blotting: Correlative studies
immunohistochemistry staining method: Correlative studies
flow cytometry: Correlative studies
polymerase chain reaction: Correlative studies
high performance liquid chromatography: Correlative studies
mass spectrometry: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Comparative Pharmacokinetics (PK) and Pharmacodynamics (PD) of Entinostat Alone vs. Entinostat Plus Imatinib Mesylate</title>
          <description>Entinostat concentrations will be compared when administered alone or in combination with imatinib by paired Student’s t test (day 4 vs 11 concentrations) or Wilcoxon signed rank tests as appropriate. Association between exposure parameters and PD endpoints (e.g., apoptosis, histone acetylation, BCR-ABL expression) will be assessed using Fisher’s exact tests or Wilcoxon rank sum tests as appropriate.</description>
          <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predictive Values of Levels of Flow Cytometric Minimal Residual Disease (MRD) on Duration of Progression Free Survival for the Study Population</title>
        <description>Kaplan-Meier PFS curves and cumulative incidence of progression curves will be generated for patients above vs. below each threshold, and log rank will be used to compare the curves.</description>
        <time_frame>Day 29</time_frame>
        <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Entinostat and Imatinib Mesylate)</title>
            <description>Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
entinostat: Given PO
imatinib mesylate: Given PO
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies
western blotting: Correlative studies
immunohistochemistry staining method: Correlative studies
flow cytometry: Correlative studies
polymerase chain reaction: Correlative studies
high performance liquid chromatography: Correlative studies
mass spectrometry: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Predictive Values of Levels of Flow Cytometric Minimal Residual Disease (MRD) on Duration of Progression Free Survival for the Study Population</title>
          <description>Kaplan-Meier PFS curves and cumulative incidence of progression curves will be generated for patients above vs. below each threshold, and log rank will be used to compare the curves.</description>
          <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Entinostat and Imatinib Mesylate)</title>
          <description>Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
entinostat: Given PO
imatinib mesylate: Given PO
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies
western blotting: Correlative studies
immunohistochemistry staining method: Correlative studies
flow cytometry: Correlative studies
polymerase chain reaction: Correlative studies
high performance liquid chromatography: Correlative studies
mass spectrometry: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: lower limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain: bone marrow site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Patrick Brown</name_or_title>
      <organization>Johns Hopkins Sidney Kimmel Cancer Center</organization>
      <phone>410-614-4915</phone>
      <email>pbrown2@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

